Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527713 | 1.00 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| P-Xylene SCHEMBL8660591 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL1705904 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL5068661 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL31313 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL29991938 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL11432043 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL34 | 0.89 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL6621981 | 0.87 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| Methoxymethane SCHEMBL3404680 | 0.86 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135181-B2 | Treatment for depression and depressive disorders | MEDLAB IP PTY LTD (AU) | 2021-10-05 | — | — | US | claimed |
| US-20200093739-A1 | SOFT CHEWS WITH LOW WATER ACTIVITY AND METHODS OF MANUFACTURING SAME | FLORIDA RESEARCH GROUP LLC | 2020-03-26 | — | — | US | claimed |
| US-20170312232-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2017-11-02 | — | — | US | claimed |
| EP-3212191-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | Medlab IP Pty Ltd. (AU) | 2017-09-06 | — | — | EP | claimed |
| WO-2017095736-A1 | ASPIRIN SOFT GELATIN CAPSULE AS A SINGLE ACTIVE OR IN COMBINATION WITH OTHER ACTIVES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2016065419-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2016-05-06 | — | — | WO | claimed |
| EP-2249868-B1 | USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GNOSIS SPA (IT) | 2015-09-02 | — | — | EP | claimed |
| CN-102321136-B | Preparation method for S-adenosine-L-methionine disulfate tosylate | BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) | 2014-10-22 | — | — | CN | claimed |
| EP-1861075-B1 | COATED GRANULAR FORMULATIONS | GRAAL S R L (IT) | 2012-05-16 | — | — | EP | claimed |
| US-20110020301-A1 | USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GNOSIS S.P.A. (IT) | 2011-01-27 | — | — | US | claimed |
| WO-2007003447-A2 | COATED GRANULAR FORMULATIONS | TRUFFINI & REGGE' FARMACEUTICI SPA (IT) | 2007-01-11 | — | — | WO | claimed |
| US-20060275363-A1 | STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONINE AND PROCESS FOR PREPARATION THEREOF | CHEMISTRY AND HEALTH INTERNATIONAL BV (CH) | 2006-12-07 | — | — | US | claimed |
| US-7048948-B2 | Stable granulates containing S-adenosylmethionine and process for the preparation thereof | CHEMISTRY & HEALTH INTERNATIONAL BV (CH) | 2006-05-23 | — | — | US | claimed |
| US-20040106573-A1 | Stable granulates containing s-adenosylmethionine and process for the preparation thereof | CHEMISTRY & HEALTH INTERNATIONAL BV (CH) | 2004-06-03 | — | — | US | claimed |
| EP-1325740-B1 | Stable granulates containing S-Adenosylmethionine and process for the preparation thereof | CHEMISTRY & HEALTH INT BV (CH) | 2004-04-21 | — | — | EP | claimed |
| EP-1325740-A1 | Stable granulates containing S-Adenosylmethionine and process for the preparation thereof | Chemistry & Health International B.V. (CH) | 2003-07-09 | — | — | EP | claimed |
| WO-2003053412-A1 | STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONNE AND PROCESS FOR THE PREPARATION THEREOF | CHEMISTRY & HEALTH INTERNATIONAL B.V. (CH) | 2003-07-03 | — | — | WO | claimed |
| US-20020164369-A1 | Novel soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same | RAO CANAKAPALLI BHAKTAVATSALA (IN) | 2002-11-07 | — | — | US | claimed |
| WO-2002049637-A1 | A NOVEL SOFT-GELATIN CAPSULE COMPRISING S-ADENOSYLMETHIONINE AND A METHOD FOR PRODUCING THE SAME | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2002-06-27 | — | — | WO | claimed |
| EP-0501293-A1 | Use of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis determined by total parenteral nutrition | BIORESEARCH S.p.A. (IT) | 1992-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106573-A1 | Stable granulates containing s-adenosylmethionine and process for the preparation thereof | RNMT, BHMT2, GMPS | ALDH1A1 3030/4885SMN1; SMN2 2282/4885LMNA 4754/4885 |
| US-20060275363-A1 | STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONINE AND PROCESS FOR PREPARATION THEREOF | RNMT, BHMT2, MAT2A | ALDH1A1 2892/4885SMN1; SMN2 2078/4885LMNA 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.